Literature DB >> 33145728

Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.

Yong-Moon Lee1, Man Hwan Oh2, Jai-Hyang Go1, Kyudong Han3,4, Song-Yi Choi5.   

Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) is a heterogeneous entity that encompasses several subtypes with distinct molecular characteristics. The patients with TNBCs show unpredictable response to the chemotherapy, and further there is the lack of effective agents. Thus, many studies have been underway to discover targeted therapy suitable for patients with specific genetic alterations in each molecular subtypes. TNBCs are classified as four major molecular subtypes according to the gene expression patterns. These are luminal androgen receptor (LAR), mesenchymal-like, immunomodulatory (IM), and basal-like types.
CONCLUSION: Here, we discuss the unique molecular features of each subtype as well as promising targets for anti-cancer therapy.

Entities:  

Keywords:  Breast cancer; Molecular diagnosis; Precision medicine; Triple negative breast cancer

Mesh:

Year:  2020        PMID: 33145728     DOI: 10.1007/s13258-020-01014-7

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  7 in total

1.  Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells.

Authors:  Ji Sun Lee; Yunmoon Oh; Jin-Sol Lee; Jae Hyeon Park; Joo-Kyung Shin; Joo-Hee Han; Hyung Sik Kim; Sungpil Yoon
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

2.  Kinesin Family Member 2A Serves as a Potential Biomarker Reflecting More Frequent Lymph Node Metastasis and Tumor Recurrence Risk in Basal-Like Breast Cancer Patients.

Authors:  Hua Yang; Yongjun Liu
Journal:  Front Surg       Date:  2022-06-16

3.  Molecular Subtyping of Cancer Based on Robust Graph Neural Network and Multi-Omics Data Integration.

Authors:  Chaoyi Yin; Yangkun Cao; Peishuo Sun; Hengyuan Zhang; Zhi Li; Ying Xu; Huiyan Sun
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

4.  MiR-21 Is Required for the Epithelial-Mesenchymal Transition in MDA-MB-231 Breast Cancer Cells.

Authors:  Elif Damla Arisan; Ozge Rencuzogullari; Clara Cieza-Borrella; Francesc Miralles Arenas; Miriam Dwek; Sigrun Lange; Pinar Uysal-Onganer
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

Review 5.  Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach.

Authors:  Sufia Islam; Nazia Hoque; Nishat Nasrin; Mehnaz Hossain; Farhana Rizwan; Kushal Biswas; Muhammad Asaduzzaman; Sabera Rahman; David W Hoskin; Saki Sultana; Christian Lehmann
Journal:  Life (Basel)       Date:  2022-06-27

6.  Genomic mapping of copy number variations influencing immune response in breast cancer.

Authors:  Igor López-Cade; Vanesa García-Barberán; Esther Cabañas Morafraile; Cristina Díaz-Tejeiro; Cristina Saiz-Ladera; Adrián Sanvicente; Pedro Pérez Segura; Atanasio Pandiella; Balázs Győrffy; Alberto Ocaña
Journal:  Front Oncol       Date:  2022-09-01       Impact factor: 5.738

Review 7.  The Roles of DNA Demethylases in Triple-Negative Breast Cancer.

Authors:  Shoghag Panjarian; Jean-Pierre J Issa
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.